Merck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist
18 Dezember 2024 - 12:45PM
Business Wire
Merck (NYSE: MRK), known as MSD outside of the United States and
Canada, and Hansoh Pharma, a Chinese biopharmaceutical company,
today announced that they have entered into an exclusive global
license agreement for HS-10535, an investigational preclinical oral
small molecule GLP-1 receptor agonist.
“We continue to leverage science-driven business development to
augment and complement our robust pipeline,” said Dr. Dean Y. Li,
president, Merck Research Laboratories. “Through this agreement, we
aim to build on our experience targeting incretin biology to
evaluate HS-10535 and its potential to provide additional
cardiometabolic benefits beyond weight reduction.”
Under the agreement, Hansoh Pharma has granted Merck an
exclusive global license to develop, manufacture and commercialize
HS-10535. Hansoh Pharma will receive an upfront payment of $112
million and is eligible to receive up to $1.9 billion in milestone
payments associated with the development, regulatory approval and
commercialization of the candidate, as well as royalties on sales.
Hansoh Pharma may co-promote or solely commercialize HS-10535 in
China subject to certain conditions. Merck will record a pre-tax
charge of $112 million, or $0.04 per share, to be included in GAAP
and non-GAAP results in the fourth quarter of 2024.
“We are pleased to announce the in-license of our oral GLP-1 by
Merck, a company with established leadership in cardiometabolic
diseases,” said Ms. Eliza Sun, Executive Director of the Board,
Hansoh Pharma. “Hansoh Pharma is becoming an emerging leader in
metabolic diseases, and we see Merck’s expertise and capabilities
as key to accelerating the development of this promising asset for
patients worldwide.”
About Hansoh Pharma
Hansoh Pharma is a leading pharmaceutical company in Greater
China driven by innovation. It is committed to the treatment of
major diseases in the areas of oncology, anti-infections, CNS
diseases, metabolic diseases, as well as autoimmune diseases, and
is dedicated to improving human health through continuous
innovation. Hansoh Pharma has been ranked among the top 100 global
pharmaceutical companies and the top 3 best industrial enterprises
in China in terms of pharmaceutical R&D pipeline for several
years and is a national key high-tech enterprise and a national
technology innovation demonstration enterprise. Hansoh Pharma was
listed on the Stock Exchange of Hong Kong in June 2019 (stock code:
03692.HK). For more information, please visit www.hspharm.com.
About Merck
At Merck, known as MSD outside of the United States and Canada,
we are unified around our purpose: We use the power of leading-edge
science to save and improve lives around the world. For more than
130 years, we have brought hope to humanity through the development
of important medicines and vaccines. We aspire to be the premier
research-intensive biopharmaceutical company in the world – and
today, we are at the forefront of research to deliver innovative
health solutions that advance the prevention and treatment of
diseases in people and animals. We foster a diverse and inclusive
global workforce and operate responsibly every day to enable a
safe, sustainable and healthy future for all people and
communities. For more information, visit www.merck.com and connect
with us on X (formerly Twitter), Facebook, Instagram, YouTube and
LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Rahway,
N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA
(the “company”) includes “forward-looking statements” within the
meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
There can be no guarantees with respect to pipeline candidates that
the candidates will receive the necessary regulatory approvals or
that they will prove to be commercially successful. If underlying
assumptions prove inaccurate or risks or uncertainties materialize,
actual results may differ materially from those set forth in the
forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and health care
legislation in the United States and internationally; global trends
toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s Annual
Report on Form 10-K for the year ended December 31, 2023 and the
company’s other filings with the Securities and Exchange Commission
(SEC) available at the SEC’s Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241218761534/en/
Merck Media: Robert Josephson (203) 914-2372
Justine Moore (347) 281-3754
Merck Investor: Peter Dannenbaum (732) 594-1579
Steven Graziano (732) 594-1583
Merck (NYSE:MRK)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Merck (NYSE:MRK)
Historical Stock Chart
Von Dez 2023 bis Dez 2024